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HIV Prevention Through Early Detection
and Treatment of Other Sexually Transmitted
Diseases — United States
Recommendations of the Advisory Committee
for HIV and STD Prevention
Summary
In May 1997, the Advisory Committee for HIV and STD Prevention (ACHSP)
reviewed data on the relation between curable sexually transmitted diseases
(STDs) and the risk for sexual transmission of human immunodeficiency virus
(HIV). ACHSP considered that the evidence was strong that early detection and
treatment of other STDs is an effective strategy for preventing sexually transmit-
ted HIV infection but was concerned that this strategy has not been clearly
articulated or implemented as a core strategy for HIV prevention in the United
States. In the context of persistently high prevalence of STDs in many parts of
the United States and with emerging evidence that the U.S. epidemic of HIV
infection and acquired immunodeficiency syndrome (AIDS) increasingly is af-
fecting population groups with the highest rates of curable STDs, ACHSP
recommends the following actions:
• Early detection and treatment of curable STDs should become a major, explicit
component of comprehensive HIV prevention programs at national, state, and
local levels.
• In areas where STDS that facilitate HIV transmission are prevalent, screening
and treatment programs should be expanded.
• HIV and STD prevention programs in the United States, together with private
and public sector partners, should take joint responsibility for implementing
this strategy.
INTRODUCTION
The Advisory Committee for HIV and STD Prevention (ACHSP) provides oversight
and guidance to CDC in the prevention of human immunodeficiency virus (HIV) — the
virus that causes acquired immunodeficiency syndrome (AIDS) — and other sexually
transmitted diseases (STDs). On May 2, 1997, ACHSP reviewed data on the role of STD
detection and treatment in the prevention of HIV infection. Based on this review,
ACHSP concluded that early detection and treatment of curable STDs should be im-
plemented more widely as an HIV prevention strategy in the United States. CDC is
disseminating these ACHSP recommendations to HIV prevention community plan-
ning groups, prevention specialists, and policymakers who address HIV and STD
prevention.
ACHSP also notes that early detection and treatment of STDs should be only one
component of a comprehensive HIV prevention program, which also must include a
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range of social, behavioral, and biomedical interventions. Furthermore, a comprehen-
sive national program for STD prevention must address other health concerns (e.g.,
STD-related infertility or adverse outcomes of pregnancy), and it requires diverse
activities that go beyond early STD detection and treatment. Also, these recommenda-
tions focus on the major treatable STDs — genital chlamydial infections, gonorrhea,
syphilis, and chancroid — because of the strong evidence of their cofactor role in HIV
transmission. Also, prevention programs and routine public health surveillance for
these conditions already exist in the United States. However, several studies indicate
that treating other STDs (e.g., genital herpes infections and trichomoniasis) and geni-
tal tract syndromes related to sex (e.g., bacterial vaginosis) also can help prevent HIV
transmission.
BACKGROUND
Curable STDs as Cofactors for HIV Transmission
Epidemiologic Evidence
Since the beginning of the AIDS epidemic, researchers consistently have noted a
strong epidemiologic association between HIV/AIDS and other STDs in developing
and industrialized countries, including the United States (1,2 ). The mutually reinforc-
ing nature of these infectious processes has been termed “epidemiological synergy”
(1 ). Diverse observational studies, including cross-sectional studies and cohort stud-
ies of HIV seroconvertors, have indicated at least a twofold to fivefold increased risk
for HIV infection among persons who have other STDs, including genital ulcer
diseases and nonulcerative, inflammatory STDs (3-12 ). These “STD cofactor effects”
were corroborated for each of the major specific genital ulcer pathogens —
Treponema pallidum (the agent of syphilis), Hemophilus ducreyi (the agent of chan-
croid), and herpes simplex virus type 2 (HSV-2, the agent of genital herpes) — as well
as for the pathogens principally responsible for nonulcerative STDs — Neisseria gon-
orrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis. More recently,
evidence has suggested that bacterial vaginosis, which is not strictly an STD but is
related to sexual behavior, also can be linked to increased risk for HIV infection (13 ).
Biologic Mechanisms
Several studies have explored potential biologic mechanisms by which other STDs
can facilitate sexual transmission of HIV infection by increasing infectiousness or sus-
ceptibility. HIV is detected routinely in the exudate of genital ulcers from HIV-infected
men and women (14-17 ). Ulcers bleed easily and can come in contact with vaginal,
cervical, oral, urethral, and rectal mucosa during sex. In men and women, inflamma-
tory STDs (e.g., gonococcal and chlamydial infections) appear to increase both the
prevalence of HIV shedding and the HIV RNA copy number or “viral load” in genital
secretions (17-20 ). Thus, these STDS are likely indicators of HIV infectiousness (1,21 ).
In HIV-infected men, gonococcal infection increases shedding of HIV RNA in semen
tenfold, but effective treatment of gonorrhea rapidly reduces HIV shedding to back-
ground levels (20 ). In addition, both ulcerative (e.g., herpes, syphilis, and chancroid)
and nonulcerative STDs (e.g., gonorrhea and chlamydia) attract CD4+ lymphocytes to
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either the ulcer surface (22 ) or the endocervix (23 ), which disrupts epithelial and mu-
cosal barriers to infections and establishes a potential mechanism to increase a
person’s susceptibility to HIV infection.
Intervention Trials
To test these epidemiologic and biologic findings, two community-level, random-
ized controlled intervention trials have been conducted. One trial, in the Mwanza
district of Tanzania, documented that continuous provision of improved STD treat-
ment reduces the acquisition of HIV infection (24 ). In that study, providing effective
drugs for STDs and training health-care providers to treat symptomatic STDs resulted
in a 38% lower HIV incidence in six intervention communities compared with six
matched control communities (Figure 1). This lower HIV incidence was not accompa-
nied by changes in sexual behavior or by condom use that might confound the direct
association between improved STD treatment and lowered HIV incidence. This ran-
domized controlled trial (RCT) was the first documented intervention that successfully
reduced HIV incidence at the population level. This study suggests that treatment of
symptomatic STDs is an effective, community-level strategy for HIV prevention in set-
tings and subpopulations in which HIV infection and other STDs are prevalent.
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Source: Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually trans-
mitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet
1995;346:530–6.
FIGURE 1. Randomized trial of improved sexually transmitted disease (STD) treatment
to prevent human immunodeficiency virus (HIV) transmission — Mwanza, Tanzania
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and $10 (U.S.) per disability-adjusted life-year (DALY) saved, compared favorably with
other highly effective public health interventions (e.g., childhood vaccinations, which
costs $12–$17 [U.S.] per DALY) (25 ).
The second trial took place in the Rakai District of Uganda and used an alternative
approach: intermittent mass STD treatment administered in a blinded fashion every
ten months (26 ), as opposed to the continuous, enhanced treatment of symptomatic
STDs in Mwanza, Tanzania. Early results of the Rakai study indicate no difference in
the incidence of HIV infection between intervention and control areas, despite signifi-
cant reductions in curable STDs in the intervention areas (27 ).
Important differences distinguish the two studies. These differences could help the
public health community assess which STD interventions are most effective in influ-
encing HIV transmission. An important factor may be continuous efforts compared
with intermittent or episodic service delivery, even when the latter is highly intensive.
A second could be the stage of an HIV epidemic: at the time of the first trial, Mwanza
was experiencing a relatively early HIV epidemic, with community HIV prevalence of
4%, whereas the Rakai study took place in one of the world’s most mature epidemics,
with a community HIV prevalence of approximately 16% (28 ). These factors and oth-
ers could have contributed to the differing outcomes of these studies, and additional
investigation is needed. 
The results of these two intervention trials reinforce the importance of ongoing
operational research to identify the strategies most effective for HIV prevention (29 ).
Public health officials should assess the epidemiologic context of the HIV and STD
epidemics based on the available data (i.e., epidemiologic associations, biologic
mechanisms, and intervention trial results) to plan and monitor implementation of
early detection and treatment of STDs to prevent HIV infection in the United States.
Other Strategies for Reducing STDs for HIV Prevention
Mathematical modeling of the biologic effects of other STDs on HIV infectiousness
and susceptibility has documented that standard epidemiologic measures of effect
(e.g., odds ratios or relative risks) might substantially underestimate the effect of STDs
on HIV transmission (30,31 ). This underestimation occurs because standard meas-
ures do not consider the effects of STD cofactors on ongoing HIV transmission.
Models suggest that STD incidence and prevalence could be critical determinants of
whether sustained heterosexual HIV epidemics can persist in subpopulations with dif-
ferent levels of risky sexual behavior (32 ).
Modeling also suggests other findings relevant to the role of STD treatment in a
comprehensive approach to HIV prevention. First, models have demonstrated a sub-
stantially greater effectiveness and cost-effectiveness when STD prevention is
implemented early in an HIV epidemic, before widespread dissemination of infection
(33–36 ). The greater impact of the Tanzania study (24 ) compared with the Ugandan
study (27 ) appears to corroborate this prediction. Second, directing STD interventions
toward persons at highest risk for acquiring and transmitting infection with HIV and
other STDs will generate a greater impact on the subsequent course of an epidemic
(34, 36, 37 ). Empiric evidence of these findings is available from interventions that
improved STD services for female sex workers in countries where HIV transmission
was strongly associated with commercial sex (10,38 ).
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Intersecting Epidemics of HIV Infection and Other STDs
As discussed previously, concurrent STDs increase the transmission probability for
HIV infection. In addition to this STD cofactor effect, the impact of other STDs on HIV
transmission will depend on a) the magnitude of the epidemics of other STDs in the
population and b) the extent to which the epidemiology of curable STDs overlaps that
of HIV infection.
Magnitude of STD Epidemics in the United States
The United States has the highest rates of STDs in the industrialized world (39 ). In
1996, approximately 400,000 genital C. trachomatis infections were detected and re-
ported to CDC (40 ), making this infectious disease the most commonly reported in the
United States (41 ), despite continuing evidence that screening is limited even among
the highest risk groups (42,43 ). Although gonorrhea incidence in the United States
declined nearly 60% during 1980–1996 (40,44 ), the 1996 rate of 124/100,000 was
26 times greater than the rate in Germany (4.7) and 50 times the rate in Sweden (2.4).
The total rate of syphilis in the United States in 1996 was 20.2/100,000 — 13 times
higher than the rate in Germany (1.5) and 33 times higher than the rate in Sweden
(0.6). Although it is not a curable STD, the prevalence of infection with HSV-2 (a
chronic, persistent viral infection) actually increased by 30% during the first 15 years
of the AIDS epidemic in the United States; by 1991, a total of 22% of all U.S. adults, an
estimated 45 million persons, were infected with HSV-2 (45 ). This often underrecog-
nized burden of STDs in the United States led the Institute of Medicine to issue a
landmark report on STDs and their prevention in the United States (39 ). In this report,
the Institute of Medicine estimated the 1994 cost of sexually transmitted HIV infec-
tion at $6.7 billion and the cost of other STDs and their immediate sequelae at
$10 billion (39 ).
Against this backdrop of high overall STD rates and costs, some subpopulations
experience even higher-than-average incidence and prevalence of STDs. Sexually
active adolescents in most parts of the United States, regardless of race or socioeco-
nomic status, have a point prevalence for chlamydial infection of 5%–10% (46 ). In
1996, routine notifiable disease reporting alone indicated a gonorrhea case rate of 3%
for African-American women aged 15–19 years and men aged 20–24 years in the
United States (40 ). Reported rates of primary and secondary syphilis in the United
States are approximately fiftyfold higher among African Americans than whites (40 ).
Men who have sex with men (MSM), especially young MSM, continue to have high
rates of STDs (47,48 ). STD prevalence rates also are typically high among persons
who use illicit drugs, including both injecting-drug users (IDU) and noninjecting-drug
users. In terms of geographic variation, bacterial STD rates are higher in many large
cities and sharply higher in the southeastern United States than for the country as a
whole (40,49 ). Superimposed on the high prevalence of STDs overall in the United
States, the higher rates within these demographic or geographic subgroups suggest
that the potential for reducing STD prevalence in these groups could be especially
large.
Vol. 47 / No. RR-12 MMWR 5
Intersecting Epidemiology of HIV Infection with Curable STDs
The potential impact of STDs in facilitating HIV transmission depends not only on
the magnitude of the STD cofactor effects and the overall STD prevalence rates, but
also on the extent to which other STDs are concentrated disproportionately among
persons and subpopulations likely to be exposed to HIV infection. STD/HIV coinfection
rates can be one indicator of this epidemiologic interaction, which heightens the po-
tential contribution of curable STDs to the sexual transmission of HIV infection.
For example, a much higher prevalence of HIV coinfection exists among persons
with any STDs than among those without STDs or a history of STDs (1,50–52 ). Conse-
quently, interventions directed toward any person with an STD are targeted
intrinsically to persons with a higher prevalence of and at higher risk for HIV infection.
Among persons with STDs, the likelihood of HIV coinfection typically is high among
persons with ulcerative STDs, reflecting shared risk factors and the strong, mutually
reinforcing effects of ulcerative STDs and HIV infection on ulcer persistence and HIV
transmissibility (1 ). For example, a recent multicenter study of syphilis therapy in the
United States documented an 18% prevalence of HIV infection among patients with
early syphilis in several large cities in the United States (53 ). A study from New York
(city), which has a longstanding HIV/AIDS epidemic, reported a tendency toward
increasing HIV prevalence over time among genital ulcer disease patients, even in an
STD clinic setting with declining overall rates of HIV infection (50 ). A newly ree-
merging syphilis epidemic in Baltimore was concentrated among HIV-infected
persons, with HIV/syphilis coinfection rates of 18% — higher than the 3% HIV preva-
lence observed among other STD clinic patients (54 ). These examples reinforce the
need to detect, treat, and prevent bacterial ulcerative STDs wherever they persist (55 )
or reemerge (56 ) in a community.
Although HIV coinfection rates typically are higher-than-average among persons
with ulcerative STDs, the high incidence and prevalence of the major nonulcerative
STDs, especially chlamydia and gonorrhea (40 ), suggests that their population-
attributable risk for promoting sexual transmission of HIV infection could be even
greater (1 ). Moreover, data from the Supplement to HIV/AIDS Surveillance (SHAS)
project and other studies demonstrate that, despite the markedly high prevalence of
HIV infection among genital ulcer disease patients, the incidence of nonulcerative
STDs among HIV-infected persons could be higher than the incidence of genital ulcer
disease (57,58 ).
In addition to these considerations related to persons infected with different STD
pathogens, subpopulations at increased risk for HIV transmission typically have
higher rates of STDs. For example, despite substantial declines since the beginning of
the AIDS epidemic, MSM continue to have high rates of bacterial and other STDs
(48,59 ), and outbreaks of gonorrhea continue to occur (47 ). Notably, the occurrence
of other STDs continues to be an important predictor of HIV seroconversion among
young MSM (59 ). Also, although parenteral exposure through contaminated injection
equipment is paramount among IDUs, they are at risk for sexual HIV transmission, as
well. In one study of female IDUs, for example, syphilis was identified as a prominent
risk factor for acquiring new HIV infection, a finding that suggests sexual transmission
could account for an underrecognized subset of new HIV infections in this group (60 ).
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Recent Shifts in the HIV/AIDS Epidemic in the United States
The U.S. HIV/AIDS epidemic has evolved recently in three ways that suggest that
STD cofactor effects are becoming increasingly important. First, heterosexual HIV
transmission is responsible for the most rapidly increasing subset of U.S. AIDS cases,
having increased both proportionately and absolutely (61 ), despite recent evidence
that the epidemic is leveling off within some other subpopulations (62 ). Heterosexual
HIV transmission is particularly important among women <25 years, accounting for
more than half of AIDS cases in this group in 1996 (61 ). As noted previously, evidence
exists for a prominent STD cofactor effect related to heterosexual HIV transmission
(1,2,24,63,64 ).
Second, the most striking recent subpopulation increase in AIDS in the United
States is among women, particularly young African-American women (61,62 ), among
whom the prevalence of other STDs also is disproportionately high (40 ). The shift in
the HIV/AIDS epidemic toward African Americans reflects, and could in part be attrib-
utable to, the long-standing disproportionate burden of other STDs in this group. It
also is closely related to the increasing prevalence of heterosexual HIV transmission,
which reinforces the importance of routine screening for asymptomatic STDs, be-
cause the proportion of STDs that are asymptomatic is higher among women than
men. 
Third, an increasing proportion of all AIDS cases (62 ) and AIDS cases among
young women (61 ) are being reported in the southeastern United States, a trend that
reflects the geographic distribution of notifiable STDs (e.g., gonorrhea and syphilis)
nationwide (Figure 2) (40,44,49 ). Like other trends, the geographic overlap between
U.S. regions (e.g., the South) that have the highest STD rates and those with the most
rapidly expanding epidemic of heterosexual AIDS and HIV infection (61,64 ) suggests
a need to strengthen early STD detection and treatment among persons at risk for HIV
infection.
Current Status of STD Clinical Services in the United States
Access to and Quality of Care in STD Clinics
Widespread availability of good-quality clinical STD services is essential to ensur-
ing that infections are detected and treated to help reduce the risk for STD and HIV
transmission (39 ). However, persons living in the United States currently have limited
awareness of their need for STD services, as well as limited access to these services.
Nearly one out of five persons living in the United States think that all STDs are cur-
able, and more than half do not know that other STDs facilitate HIV transmission (39 ).
Only half of local public health departments in the United States provide STD preven-
tive services, compared with 96% that provide vaccinations (Figure 3) (65 ). Even
where STD services are provided, access to care often is restricted by limited hours
of operation and the lack of timely services (66 ). Nearly 40% of local health depart-
ments that provide STD services cannot see potentially infected (and infectious) new
patients the same day they seek care, and 15% cannot see such patients for 3 days or
more (65 ).
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STD Services Outside Public Health Clinics
As a result of changing health-care systems in the United States, most patients with
STDs, especially women, are not examined in public STD clinics. In primary-care set-
tings, even if persons are examined by a clinician, most providers do not routinely
obtain a sexual history or ask about or screen for STDs (42,67 ).
To address this problem, innovative approaches to delivering STD clinical care out-
side of categorical STD clinics are being explored. Integration of STD care and
family-planning services within a broader reproductive health model provides
efficient health care for women and has been highly successful as a primary strategy
for reducing chlamydial infections in the United States (68 ). Prenatal and obstetrical-
care settings also provide a venue for STD/HIV screening and prevention, while
enhancing the potential for prevention of perinatal HIV transmission (69 ) and other
STD-related adverse outcomes of pregnancy (70,71 ). Recognition that public-sector
STD services cannot reach all persons who need them has prompted additional efforts
to reach private providers (72,73 ). Specific strategies include promoting improved
Counties with primary and secondary syphilis 
>10 per 100,000 population (n = 461) in 1993
States with gonorrhea rates >225 per 100,000 
population in 1993
Health districts with HIV seroprevalence >1 per 1,000 
population in women who bore children in 1994
Source: St Louis ME, Wasserheit JN, Gayle HD. Janus considers the HIV pandemic—
harnessing recent advances to enhance AIDS prevention [Editorial]. Am J Public Health
1997;87:10-2.
FIGURE 2. Health districts with the highest human immunodeficiency virus (HIV)
seroprevalence among women who bore children in 1994, counties reporting the
highest primary and secondary syphilis rates in 1993, and states reporting the highest
gonorrhea rates in 1993 — United States
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STD services within managed care organizations (MCOs) (74 ), which are emerging as
a dominant medical-care system in much of the United States (75 ), particularly for the
more disadvantaged subset of the population at higher risk for HIV infection. For ex-
ample, the role of MCOs was specifically considered in the development of the
Institute of Medicine report, The Hidden Epidemic, and MCO representatives helped
develop the 1998 Guidelines for Treatment of Sexually Transmitted Diseases, which is
used to set STD practice standards in the United States (76 ). Additional efforts
have been undertaken with providers who care for other critical subpopulations with
high rates of STDs (e.g., adolescents) (73 ), but these efforts need to be increased
substantially.
Establishing STD clinical services in nonclinical, institutional, or community
settings typically is more expensive than clinic-based approaches but could yield sub-
stantial benefits if services are extended to persons at higher-than-average risk for
acquiring or transmitting STDs within communities (77,78 ). New STD diagnostic
methods that use urine, self-collected swabs, or other noninvasive specimens will
permit direct outreach to persons who might not effectively access any formal health-
service setting (79,80 ). In addition, the recent approval of rapid HIV tests and tests that
use oral fluids as a specimen (81-83 ) could facilitate the widespread use of HIV testing
and counseling in STD care settings, particularly nontraditional ones.
Community outreach for STD prevention is limited in many jurisdictions (Figure 3)
(65 ), particularly outside dedicated STD clinics or in other venues where there are
persons at higher-than-average risk for STD or HIV infection. For example, although
U.S. prisons have expanded screening programs for HIV infection in recent years, STD
screening and prevention remains less common (84 ). Fewer than half of U.S. jails
(85 ) offer routine STD detection and treatment programs, despite their documented
high yield and impact (77,86 ).















On same day new clients seek care
STD clinical services provided:
Provided on site:
Spent >$40,000/year on STD services
Conducted community/street
  outreach
Source: Landry DJ, Forrest JD. Public health departments providing sexually transmitted disease
services. Fam Plann Perspect 1996;28:261–6.
FIGURE 3. Sexually transmitted disease (STD) prevention services in local health
departments — United States, 1995
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Importance of Asymptomatic Infections 
An often unrecognized aspect of STDs, including bacterial STDs, is how frequently
persons with these infections have no symptoms or do not recognize symptoms. Most
studies of STDs are conducted in health-care settings specifically for persons who do
recognize symptoms; therefore, these studies usually overestimate the proportion of
infected persons who are symptomatic. Studies of STD screening in nonhealth-care
settings (e.g., jails, workplaces, and communities) or health-care settings where STD
treatment is not the primary function (e.g., family-planning clinics) suggest that most
persons with gonorrhea or chlamydia are asymptomatic. Among women seeking con-
traceptive or other gynecologic services, 52% of those with gonorrhea and at least
70% of those with chlamydial infection exhibited neither symptoms nor signs of infec-
tion (87,88 ). Four population-based studies of men documented that 68%-92% of
those with gonorrhea reported no symptoms (89-92 ), and one study reported that
92% with chlamydia reported no symptoms (92 ).
This common lack of symptoms for gonorrhea and chlamydia has important impli-
cations for treatment of these STDs, as well as for the way in which STD treatment can
be used for HIV prevention. Providing access to treatment for persons with STD symp-
toms is an essential aspect of STD and HIV prevention, but most curable STDs will go
unrecognized and untreated without increased efforts to detect and treat persons
without symptoms. Opportunities to identify and treat asymptomatically infected per-
sons include screening in health-care settings when persons are present for other
problems (e.g., in emergency rooms or family-planning clinics, during routine or an-
nual physical examinations, and during vaccination visits for adolescents and adults)
and in nonhealth-care settings (e.g., schools and jails). Screening also can be con-
ducted through sex-partner-notification programs.
RECOMMENDATIONS
Initial Steps to Enhance STD Detection and Treatment
Considering the data presented previously, ACHSP recommends that early detec-
tion and treatment of curable STDs that facilitate HIV transmission should be a central
and explicit component of national, state, and local strategies to prevent HIV infection
and AIDS. Although enhancing STD screening and treatment has always been desir-
able as a way to prevent the complications of STDs, current knowledge indicates it
also is critical to preventing HIV infection. Any activity that decreases the incidence
and prevalence of STDs in a population will decrease the prevalence of this key cofac-
tor and should therefore decrease HIV transmission. Thus, health-care providers could
prevent HIV transmission not just by treating STDs among persons with HIV infection,
but also by treating and preventing STDs among any persons at risk for STDs. Other
strategies to help achieve these goals are improving access to and quality of STD
clinical services, expanding screening and treatment for STDs in medical settings, and
establishing or expanding screening for STDs in nonmedical settings.
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Improving Access to and Quality of STD Clinical Services
A basic step toward implementing this strategy is to provide timely, good-quality
STD clinical care to persons who recognize or suspect symptoms of STDs or who
suspect they have been exposed and seek STD clinical care on their own. A major
component of the randomized controlled trial in Mwanza was the simple enhance-
ment of the quality of clinical STD services for symptomatic persons, which was
recognized by the population and translated rapidly into increased use of services
(24 ). Better and faster methods are needed to assess effective access to STD clinical
care in communities, and strategies are needed to extend services rapidly to those in
need and at risk for HIV and STD transmission. Accordingly, ACHSP makes the follow-
ing recommendations:
• Basic clinical services (i.e., STD diagnosis and treatment) should be readily avail-
able to all sexually active adults and adolescents in the United States who believe
they have been exposed to or have symptoms of an STD. These services should
be accessible without fees or with only nominal fees (i.e., clients with symptoms
should not be denied care because of inability to pay), available at least five days
per week, and available the same day that care is sought (i.e., without advanced
appointments being required). These services can be provided in categorical
public STD clinics but also should be available in other primary-care settings,
including hospital walk-in clinics, community and migrant-worker health centers,
family-planning clinics, clinics for adolescents, primary-care physicians’ offices,
and clinics in MCOs or integrated inpatient/outpatient provider institutions.
In particular, HIV-infected persons with STD symptoms need to be able to obtain
STD diagnosis and treatment easily, and STD services should be a routine part of
quality HIV care. Furthermore, presumptive treatment should be available at no
cost or nominal cost to sex partners of persons with STDs. In particular, MCOs
should provide treatment services to sex partners of enrollees with STDs, even if
Initial steps for improving sexually transmitted disease (STD) detection and
treatment to prevent human immunodeficiency virus (HIV) transmission
1. Assess and ensure timely access to high-quality STD clinical care for persons
seeking medical services for symptoms of STDs in private and public medi-
cal-care settings. 
2. Screen for asymptomatic or unrecognized STD infections in medical-care set-
tings according to current guidelines, and expand screening as needed based
on prevalence of infections detected in pilot screening efforts. 
3. Establish or expand STD screening in nonmedical settings where persons at
high risk for HIV infection and curable STDs are encountered and can be
treated efficiently, including jails and other correctional facilities, substance
abuse treatment centers, and hospital emergency departments. 
4. Provide cross-training to program and management staff, including HIV pre-
vention community planning groups, on the role of STD detection and treat-
ment in HIV prevention.
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these sex partners are not themselves enrollees. Family-planning clinics also
should provide STD diagnosis and treatment services to sex partners of their
clients.
• All health-care providers who care for persons with or at risk for STDs should be
aware of current national guidelines for STD treatment (76 ) and should provide
care according to those guidelines or to local adaptations of those guidelines.
Also, although guidelines exist for STD clinical management (76,93 ), a substan-
tial gap often exists between published guidelines and actual practice (94 ).
Therefore, CDC’s STD treatment guidelines (69 ) should be disseminated to prac-
titioners who treat STDs, as well as to those who help establish policies for
clinical practice (e.g., clinical quality promotion and assurance committees, for-
mulary committees, and other groups whose activities support good clinical
care).
• All health-care providers should receive adequate training for early detection and
treatment of STDs. Because of the ongoing rapid evolution of health care in the
United States, training needs are evolving continually. The aforementioned shift
to managed care and other changes in health delivery and financing will require
that MCO and other primary-care clinicians in diverse disciplines provide an
increasing proportion of STD clinical care. Thus, training needs for STD clinical
management will broaden, and new strategies will be needed to train the ex-
panding base of providers of STD clinical care.
To support these changes, the STD training needs of primary-care practitioners
should be assessed in all jurisdictions of the United States with a prevalence of
treatable STDs. Training plans can be developed and implemented based on this
assessment. CDC supports a national network of STD prevention training centers
to consult on STD clinical management training needs, which is accessible via
the World Wide Web at <http://Inpharmatics.uc.edu/stdptc.html>.
Enhanced Screening for STDs in Medical Settings
Because most STDs are asymptomatic, voluntary care-seeking specifically for
STD-related symptoms is unlikely to lead to detection of most infections. Thus,
STD screening programs are a critical component of expanding early detection and
treatment.
Although many persons at risk for STDs cannot or do not access health-care serv-
ices specifically for STD testing and treatment, they often do visit several health-care
settings for other purposes. Such visits currently represent missed opportunities to
diagnose and treat STDs and to decrease transmission of HIV infection. In 1996, the
U.S. Public Health Service published national guidelines for screening for syphilis,
gonorrhea, chlamydial infection, and genital herpes (93 ). Other national organizations
also have issued guidelines for screening specific population groups, such as adoles-
cents (95 ). These guidelines were developed to prevent the complications of STDs
themselves and generally do not account for the individual or population-level risk for
HIV infection caused by the presence of these STDs in individuals or communities.
Because of the impact of HIV disease on individuals and communities, ACHSP
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endorses the existing screening guidelines and extends them to include the following
recommendations:
• All sexually active females aged <25 years visiting health-care providers for any
reason should be screened for chlamydia and gonorrhea at least once per year,
unless screening in that setting has been documented to yield a low prevalence
of infection (e.g., <2% using sensitive tests). In a low-prevalence population,
more selective screening criteria (96 ) or more sensitive laboratory tests can
be used. Examples of health-care settings in which this screening can occur are
family-planning clinics, prenatal clinics, emergency rooms and walk-in clinics,
community and migrant-worker health centers, clinics for adolescents, school-
based clinics, clinics in correctional facilities, and primary-care provider offices
(during routine physical examinations).
• All young, sexually active men should be screened routinely for chlamydial and
gonococcal infections, which is increasingly feasible and acceptable because of
new diagnostic tests that allow the use of urine as a specimen for screening. In
the absence of well-defined screening criteria, the prevalence of infections can be
assessed in clinical settings where young men are accessible, and routine
screening should be implemented in settings or subpopulations in which the
prevalence is high (e.g., ≥2%). Examples of health-care settings in which this
screening can occur are emergency departments, walk-in clinics, community and
migrant-worker health centers, clinics for adolescents, school-based clinics, clin-
ics in correctional facilities, and primary-care provider offices (during routine
physical examinations). Adolescent and young MSM particularly are at high risk
for HIV infection and other STDs and constitute a critically important population
for routine STD screening (48,59 ).
• In addition to routinely screening adolescents and young adults, clinicians also
should provide chlamydia and gonorrhea screening at least once per year
to older, higher-risk males and females visiting health-care providers for any rea-
son. Examples of higher-risk persons are those who abuse substances, persons
with a history of STDs or more than one sex partner per year, those in correc-
tional facilities, and persons from communities with high rates of STDs.
Determination of high-risk status also should take into account the prevalence of
HIV infection in the subpopulation being considered. Health-care providers and
public health agencies should use these screenings to collect sufficient data
about the local prevalence of STDs and the risk factors for positivity to develop
locally relevant definitions of high-risk status.
• Serologic screening for syphilis should be conducted in high-risk persons (e.g.,
those with multiple sex partners or who have exchanged sex for money or drugs,
persons admitted to jails, and users of illicit drugs). Because syphilis rates in the
United States vary considerably by region and among subpopulations within
high incidence regions, local epidemiologic data and pilot testing can be used to
guide local screening efforts. Syphilis screening should be more routine in juris-
dictions with high incidence rates (e.g., notified rates greater than the Healthy
People 2000 goal of 4/100,000 cases of primary and secondary syphilis). It
also should be expanded rapidly during outbreaks and extended to persons
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encountered in emergency departments of public hospitals and other clinical or
community venues with an appreciable prevalence of syphilis.
• Persons already infected with HIV should be screened routinely for STDs. Early
STD detection and treatment in this subpopulation could be particularly effective
and cost-beneficial in reducing HIV transmission for three reasons: most STDs
promote increased shedding of HIV (1,20 ); the number of HIV-infected persons is
smaller than the number of persons at risk for becoming infected; and HIV-
infected persons often are receiving regular medical care.
Specifically, all HIV-infected persons who might be at risk for STD acquisition
should be screened regularly for curable STDs, including gonorrhea, chlamydial
infection, syphilis, and — among women — trichomoniasis. In addition, persons
with HIV/AIDS should be assessed for genital herpes, educated about symptoms
of herpes, and counseled to particularly avoid sex during periods with symptoms
of reactivation of genital herpes, which are associated with higher rates of HIV
viral shedding (16 ). Screening frequency should depend on the person’s risk be-
havior, the potential risk behavior of the person’s partner(s), and the incidence of
STDs in the local population, but generally should occur at least yearly if any
potential risk exists for STD acquisition. It should be performed more frequently
if any incident STDs are detected by symptoms or screening. These services
should be provided as part of and at the site of routine, quality HIV care.
Counseling Persons with HIV/AIDS and a New STD
The presence of a new STD in a person with HIV/AIDS strongly suggests unpro-
tected sex, a behavior that could place another person or persons at risk for HIV
infection. Counseling should consist of several components, including the following:
• Determining the type and frequency of sexual behaviors that have occurred.
• Determining the number and HIV-infection status of the partner(s) with whom the
person with HIV/AIDS and a new STD has had sex.
• Counseling the person with HIV/AIDS and a new STD on the need to eliminate
unprotected sex, especially with persons of unknown or negative HIV-infection
status, and on the role other STDs play in facilitating HIV transmission to other
persons.
• Counseling the person with HIV/AIDS and a new STD on issues related specifi-
cally to STD treatment and prevention, including avoidance of future STDs,
proper screening and evaluation for STDs, and adherence to all aspects of pre-
scribed STD treatment (e.g., abstaining completely from sex for the appropriate
period following treatment with a recommended antimicrobial regimen for the
diagnosed STD) (76 ).
• Assisting with notification of the partner(s) (HIV-infected, uninfected, or unknown
status) about exposure to STD and HIV infection and the need to be evaluated,
tested, and treated.
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In addition to these counseling messages, any newly or previously identified per-
son with HIV/AIDS who is not in a high-quality HIV/AIDS treatment program should be
referred to one. 
Expanded STD Screening in Nonmedical Settings
Many persons at increased risk for STDs and HIV infection visit health-care provid-
ers infrequently, and some populations are easier to reach outside traditional clinical
settings. Newer screening tests (i.e., those using urine samples or self-obtained
swabs) make screening in nonmedical settings increasingly feasible. ACHSP makes
the following recommendations for STD screening in nonmedical settings:
• Persons entering correctional and detention facilities should be screened for
syphilis, gonorrhea, and chlamydia. When possible, females also should be
screened for trichomoniasis and bacterial vaginosis. This recommendation in-
cludes state and federal prisons, local jails and holding centers, and juvenile
detention centers. STD screening could be particularly important in jails and
other short-term facilities where many persons at high risk (e.g., those detained
for charges related to commercial sex) stay for short periods before being
released (77 ). Therefore, such screening should occur as soon as possible after
a person enters a correctional or detention facility, preferably within the first
24 hours.
• Adolescents should be screened for gonorrhea and chlamydia in institutions that
serve them, including schools, community-based programs for at-risk popula-
tions, and employment/training (e.g., Job Corps), sports, and summer youth
programs. The disease prevalence found after pilot screening should determine
the extent and frequency of screening. In general, adolescents should be tested
for these diseases at every visit if the prevalence of infection is ≥2%.
• High-risk persons in street settings should be screened for gonorrhea, chlamy-
dia, and syphilis whenever feasible during community outreach programs
designed to prevent HIV infection. This type of screening often is best accom-
plished through partnerships between health agencies and community-based
organizations or representatives of the target communities. Noninvasive diag-
nostic tests (e.g., urine tests), self-obtained specimens, and mobile clinics can
help facilitate testing in street settings. The yield or prevalence of infection de-
tected through these programs can be used to verify that appropriate groups
have been reached through outreach, with a goal of targeting screening activities
at communities or populations that yield a prevalence of ≥2%.
Presumptive Treatment for STDs
Persons with positive tests for STDs often are difficult to locate when the results
become available, and even when they are found, they have had the opportunity to
transmit the infection during the interval between testing and treatment. Because of
this risk and because of the safety of the antibiotics used to treat curable STDs,
persons likely to have these STDs should be treated presumptively while awaiting
laboratory confirmation. Presumptive antibiotic treatment for STDs has been part
of CDC’s STD treatment guidelines for many years (69). ACHSP endorses these
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guidelines, viewing them now as part of a national strategy for HIV prevention, espe-
cially in settings where the likelihood of STD infection is high or prompt follow-up
for subsequent treatment is in question. These guidelines include the following
recommendations:
• When doubts exist about whether a patient will follow up for test results or ad-
here to recommendations to avoid sexual activity while potentially infected with
an STD, men with urethral discharge and sexually active females with mucopu-
rulent cervical discharge should be treated presumptively with antibiotics for
gonorrhea and chlamydial infection (76 ). Presumptive treatment for primary
syphilis is recommended in persons who have new onset genital ulcers and are
from communities or groups with high syphilis rates. HIV-infected persons with
genital ulcers or urethritis also should receive such empiric treatment, to de-
crease the load of excreted virus as quickly as possible.
Medical providers also should consider presumptive treatment for other STDs
(e.g., trichomoniasis) and genital infections (e.g., bacterial vaginosis), depending
on clinical findings and disease prevalence in the population served. When pre-
sumptive treatment is administered, laboratory testing should be undertaken
whenever possible to confirm the nature of the infection.
• Sex partners of persons treated presumptively for curable STDs also should be
treated presumptively for these diseases. This recommendation is based on
a) the likelihood that sex partners are infected with the same organism(s) as in-
dex patients, b) the high risk for reinfection of the treated index patients by their
partners if the partners are not treated quickly, and c) the possibility that confir-
matory laboratory tests on the index patients will give false negative results.
When presumptive treatment is administered to sex partners, laboratory testing
should be undertaken whenever possible to confirm the nature of the infection.
Behavioral Issues Related to Early Detection and Treatment of STDs
Although early STD detection and treatment essentially represents a biomedical
tool for lowering the risk for sexual transmission of HIV infection, important associ-
ated behavioral issues exist. The most important new messages for persons at risk for
HIV infection and other STDs include a) other STDs facilitate HIV transmission, and
early STD detection and treatment is an HIV prevention strategy; b) recognizing and
watching for the symptoms of STDs is important; and c) most STDs produce no symp-
toms, so routine screening is crucial. A complementary set of messages should be
developed and disseminated to health-care providers, and specific information on
where to obtain quality STD services should be available to persons who need it.
These behavioral messages should supplement, not supplant, messages already
emphasized in HIV-prevention counseling, such as the advantages of reducing the
number of sex partners, the importance of knowing the HIV serostatus of one’s part-
ner(s), the importance of consistent and correct condom use, and the need to develop
and implement strategies for avoiding risky sexual and other behaviors.
16 MMWR July 31, 1998
ADDITIONAL SUPPORTIVE ACTIVITIES
HIV Screening Among Persons with Other STDs
Screening for HIV infection among persons with other STDs is an important HIV
prevention strategy. Although HIV counseling and testing among persons with other
STDs has long been recommended and applied in the United States (97 ), the extent
of the practice of this preventive service varies and is limited in many jurisdictions. A
person could be more receptive to HIV prevention messages delivered when an STD
is diagnosed. Therefore, broader practice of HIV counseling and testing among STD
patients, although not strictly pertinent to the strategy of early STD detection and
treatment, could provide an opportunity to reinforce awareness of the cofactor role of
STDs for HIV transmission and the importance of seeking timely medical care for STD
symptoms. It also provides an important opportunity to assess coinfection rates for
HIV infection and other STDs. However, these services should be implemented with
scrupulous attention to the quality of the counseling and with adequate referral sys-
tems to redirect HIV-seropositive and at-risk HIV-seronegative persons into long-term
primary-care, prevention, and drug treatment services, as appropriate.
Community-Level Prevention of the Highest Risk STDs
Some less common STDs in the United States have been associated with a higher-
than-average prevalence of HIV coinfection and transmission risk. Examples include
rectal gonorrhea among MSM and the bacterial genital ulcer diseases (syphilis and
chancroid). Rectal gonorrhea in men should be monitored carefully, and its persist-
ence should be considered a community-level sentinel event reflecting a mixture of
higher-risk behavior, STD cofactor effects, and other HIV transmission risk factors. It
should prompt an urgent HIV prevention response, including but not restricted to
enhanced STD detection and treatment among MSM.
Also, because of the strong impact of syphilis and chancroid on HIV transmission,
U.S. public health officials are developing and implementing plans to eliminate
domestic transmission of syphilis (98 ). This program could be particularly important
because of the apparent cyclical nature of syphilis epidemics in the United States in
the absence of concerted efforts toward elimination of this disease (49,55 ). Therefore,
ACHSP supports syphilis elimination as a potentially high-impact activity leading to
reduced STD-facilitated HIV transmission in the United States. It recommends that
STD and HIV prevention programs collaborate in the development and implementa-
tion of syphilis elimination plans in their jurisdictions.
Improving and Using STD Surveillance for HIV Prevention
Early detection and treatment of curable STDs as an HIV prevention strategy also
has implications for public health surveillance of STDs. Improved quality, complete-
ness, and timeliness of STD surveillance can provide critical information to target
early STD detection and treatment and help target HIV prevention strategies. If report-
ing requirements are met, expanded early detection of STDs within a jurisdiction
should lead to more complete STD surveillance data, which could be an important
element of the epidemiologic profile used by HIV prevention community planning
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groups (99 ). Although it also could lead to an increase in reported STD rates in the
initial years of expanded services, this result should be seen as a positive indicator of
enhanced early detection of STDs. The rates should decline in subsequent years.
In addition to these general concerns, several surveillance issues are important to
improving early STD detection and treatment for HIV prevention. In many areas of the
United States and nationally, data are not collected systematically on the anatomic
site of infection for persons with gonorrhea. However, gonorrhea among MSM, espe-
cially rectal gonorrhea, can be an important indicator of the potential for HIV trans-
mission. Therefore, the anatomic site of gonococcal infection should be reported con-
sistently as part of routine notifiable disease surveillance in all jurisdictions.
Enhanced STD surveillance also should include monitoring the prevalence of STDs
and HIV infection in settings where there are persons at high risk for both (e.g., correc-
tional facilities and drug treatment centers) (77,86,100,101 ). This latter surveillance
strategy complements the expanded early detection and treatment of STDs in settings
where higher-risk persons are encountered. The observed prevalence of STD and HIV
infections in these specific venues, as well as additional data when available on
STD/HIV coinfections, should be used to guide further program interventions (100 ).
Finally, HIV counseling and testing data systems should be modified to ensure that
STD diagnoses are captured.
Cross-Training HIV and STD Prevention Staff
Implementing the strategy of enhanced STD detection and treatment for HIV pre-
vention is likely to require or be enhanced by greater mutual familiarity and sense
of shared purpose within state and local HIV and STD prevention programs. Cross-
training program and management staff in the current practices, technology, and
guidelines of the other program should mutually strengthen both HIV and STD pre-
vention programs. In many jurisdictions and/or for certain subpopulations, cross-
training could be an initial activity to help adapt these general recommendations to
the specific epidemiologic, health-care, and prevention service needs of the local
population.
Potential Role of Other STDs
Although this report has emphasized early detection and treatment of curable,
especially bacterial, STDs, other STDs and related conditions also warrant appropriate
management and could constitute equally important opportunities for HIV prevention.
For example, evidence exists for a cofactor role of vaginitis caused by the common,
sexually transmitted parasite T. vaginalis, so including T. vaginalis in screening proto-
cols for women whenever feasible is likely to lower the risk for HIV transmission.
Infections with HSV-2 are highly prevalent in the U.S. population (45 )  and occur in at
least half of individuals in some subpopulations at high risk for HIV infection (e.g.,
MSM). As a persistent, latent infection causing recurring genital ulcers and associated
with greater genital tract HIV shedding (16 ), HSV-2 coinfection could represent a ma-
jor STD cofactor effect. At a minimum, persons with both HIV infection and genital
herpes should be counseled especially to avoid sex when herpes is symptomatic be-
cause HIV viral shedding is more active during such periods. However, the optimal
detection and treatment strategy corresponding to this particular STD/HIV interaction
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has not been well-defined and, for the moment, remains a critical area for needed
research. Emerging data on bacterial vaginosis as a risk factor for HIV acquisition in
women (13,102 ) likewise represent a major potential opportunity, as well as a chal-
lenge. Although bacterial vaginosis is a highly prevalent condition, no well-defined
effective strategies for long-term prevention exist beyond treating individual patients.
RESEARCH ISSUES
In addition to practical steps that can be implemented immediately, several re-
search issues need to be addressed to maximize the longer-term impact of early STD
detection and treatment as a strategy for HIV prevention. These include a) methods to
better assess, at national and local levels, the attributable risks related to different STD
pathogens; b) methods to better assess the potential prevention impact of different
approaches to enhanced STD treatment and prevention; c) protocols for assessing
access to and quality of clinical STD services in communities and for specific popula-
tions within communities; d) the prevalence of STDs and risk factors for STDs among
asymptomatic persons currently not screened for STDs (e.g., men), so screening
guidelines can be refined further; e) the incidence of curable STDs in certain high-risk
populations (e.g., HIV-infected persons), so guidelines can better specify the best fre-
quency of screening; f) the field performance and practical issues involved in using
both new and older noninvasive tests (e.g., urine tests and self-obtained swabs) to
identify STDs in nonmedical settings; g) the precise balance of benefits and risks of
presumptive or prophylactic antimicrobial therapy for persons who, based on
epidemiologic data, have extremely high rates of curable STDs; and h) the role of HSV-
2 and other viral STDs in HIV transmission and the potential role of suppressive or
other chemotherapy for genital herpes in reducing the risk for HIV transmission.
Similarly, new behavioral and operational research is required to complement, fa-
cilitate, and enhance overall HIV prevention efforts because of increased emphasis on
early STD detection and treatment. Examples include how to best provide HIV and
STD prevention counseling when asymptomatic STDs are detected and how to im-
prove HIV prevention referral systems and processes within the full range of STD
detection and treatment facilities and settings (i.e., HIV counseling and testing centers,
MCOs, and street outreach settings). Operations research also is needed to better un-
derstand how to organize STD prevention services to prevent HIV transmission.
Additional research issues will arise as the initial program activities described pre-
viously are implemented.
CONCLUSIONS
Early detection and treatment of other STDs should be a critical component of
national, state, and local strategies to prevent HIV infection and AIDS, in concert with
the behavioral and other interventions that constitute a comprehensive HIV preven-
tion approach. Because the United States has the highest rates of curable STDs
among industrialized nations (39,40 ) and a high prevalence of HIV infection (103 ), the
potential impact of enhanced STD control on the prevention of sexually transmitted
HIV infections in the United States is likely to be substantial. The initial steps outlined
in this report should be implemented by state and local HIV and STD prevention
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programs as part of a comprehensive HIV prevention effort. Evaluation of these initial
efforts should be used to guide subsequent implementation of this strategy.
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